Covaxin 77.8% effective in phase 3 trial data
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Wednesday
February 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
WEDNESDAY, FEBRUARY 01, 2023
Covaxin 77.8% effective in phase 3 trial data

Coronavirus chronicle

TBS Report
22 June, 2021, 03:55 pm
Last modified: 22 June, 2021, 04:00 pm

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • India gives conditional market nod for Covishield and Covaxin

Covaxin 77.8% effective in phase 3 trial data

Phase III trial data had been presented to the national drug regulator over the weekend and was cleared at a meeting of the SEC this afternoon

TBS Report
22 June, 2021, 03:55 pm
Last modified: 22 June, 2021, 04:00 pm
Covaxin is produced by Bharat Biotech and is one of the vaccines being used in the nationwide inoculation drive. Photo :AFP via Hindustan Times
Covaxin is produced by Bharat Biotech and is one of the vaccines being used in the nationwide inoculation drive. Photo :AFP via Hindustan Times

Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against Covid-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday.

Phase III trial data had been presented to the national drug regulator over the weekend and was cleared at a meeting of the SEC this afternoon, reports the NDTV.

The data has not yet been fully published in an internationally recognised, peer-reviewed journal; manufacturers Bharat Biotech earlier this month said publication would take place after submission to the drug regulator and within a timeline of approximately three months.

The "first interim analysis" of Phase III results, presented in March, indicated Covaxin was 81 per cent effective in preventing Covid-19 in those without prior infection after the second dose.

Data also showed a 100 per cent reduction in chances of hospitalisation in case of infection.

Covaxin was cleared for emergency use last year while still in clinical trials; it was given "restricted use in emergency situation in public interest", which raised questions and was also seen as contributing to vaccine hesitancy that marked the early stages of India's vaccination drive.

Final Phase III trial data will go a long way towards resolving doubts and concerns as the government looks to increase the pace of vaccination across the country.

Top News

COVAXIN / Bharat Biotech Covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Will reform pledges to IMF work this time?
    Will reform pledges to IMF work this time?
  • Infographic: TBS
    How to redirect inward remittances to formal channels
  • Photo: TBS
    By-polls in BNP MPs' vacant seats: Few voters in B'baria polling centres, clash in Chapainawabganj

MOST VIEWED

  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • India gives conditional market nod for Covishield and Covaxin

Features

An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

2h | Panorama
Infographic: TBS

How to redirect inward remittances to formal channels

3h | Panorama
Photo: Bloomberg

How the 'madoffs of Manhattan' can unravel Gautam Adani's empire

2h | Panorama
Photo: Collected

Tips to incorporate sustainable construction

1d | Habitat

More Videos from TBS

Alka Yagnik guinness world record

Alka Yagnik guinness world record

51m | TBS Entertainment
Interest rate should be left to market

Interest rate should be left to market

56m | TBS Round Table
Adani’s shares fell sharply after allegation

Adani’s shares fell sharply after allegation

16h | TBS World
Why Messi was blocked on Instagram?

Why Messi was blocked on Instagram?

15h | TBS SPORTS

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
Photo: Saqlain Rizve
Bangladesh

Bangladeshi university students identified as problematic users of Facebook, internet: Study

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

6
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]